Amendments to the Claims:

1. (Currently amended): A compound~~, including stereoisomers,~~ of formula (I)



(I)

or a stereoisomer ~~prodrug,~~ or a pharmaceutically acceptable salt ~~or solvate~~ thereof, wherein the dashed line may represent a double bond;

R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from:

halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, $-C(O)R_2$, nitro, hydroxy, $-NR_3R_4$, cyano, and [[or]] a group Z;

R_1 is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR_3R_4, or cyano;

R_2 is a C1-C4 alkyl, $-OR_3$, or $-NR_3R_4$;

R_3 is hydrogen or C1-C6 alkyl;

R_4 is hydrogen or C1-C6 alkyl;

R_5 is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, $-NR_3R_4$, or $-C(O)R_2$;

R_6 is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, $-NR_3R_4$, or $-C(O)R_2$;

~~R_7 is hydrogen, C1-C6 alkyl, halogen, halo, or C1-C6 alkyl;~~

R_8 is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_9 is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{10} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{11} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{12} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{13} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4, or cyano;

R_{14} is R_3 or $-C(O)R_2$;

D is CR_8R_9 or is CR_8 when double bonded with G or A;

G is $CR_{10}R_{11}$ or is CR_{10} when double bonded with D ~~or is CR_{10} when double bonded with X when X is carbon~~;

A is $CR_{12}R_{13}$ or is CR_{12} when double bonded with D;

X is ~~carbon or~~ nitrogen;

Y is nitrogen ~~or CR_7~~;

W is a 4-8 carbocyclic membered ring, which may be saturated or may contain one to three double bonds, and

in which:

- one carbon atom is replaced by a carbonyl or $S(O)_m$; and
- one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR_{14}, $S(O)_m$, carbonyl, and such ring may be further substituted by 1 to 8 R_6 groups;

Z is a 5-6 membered heterocycle or a phenyl, which may be substituted by 1 to 8 R_5 groups; and

m is an integer from 0 to 2.

2. (Currently amended): A compound according to claim 1, in which W is selected from the following groups:



in which:

W1 represents a 1,3-dihydro-2H-imidazol-2-one derivative;

W2 represents a imidazolidin-2-one derivative;

W3 represents a tetrahydropyrimidin-2(1H)-one derivative;

W4 represents a 2,5-dihydro-1,2,5-thiadiazole 1-oxide derivative;

W5 represents a 1,2,5-thiadiazolidine 1-oxide derivative;

W6 represents a 2,5-dihydro-1,2,5-thiadiazole 1,1-dioxide derivative;

W7 represents a 1,2,6-thiadiazinane 1-oxide derivative;

W8 represents a 1,2,6-thiadiazinane 1,1-dioxide derivative;

W9 represents a pyrrolidin-2-one derivative;

W10 represents a 2,5-dihydro-1,2,5-thiadiazolidine 1,1-dioxide derivative;

W11 represents a 1,3-oxazolidin-2-one derivative;

W12 represents a isothiazolidine 1,1-dioxide derivative;

W13 represents a 2(1H)-pyridinone derivative;

W14 represents a 3(2H)-pyridazinone;

W15 represents a 2,3-piperazinedione derivative;

and q is an integer from 0 to 4; n is an integer from 0 to 6; p is an integer from 0 to 3; and m, R_6 and R_{14} are defined as in claim 1~~; or a prodrug, or a pharmaceutically acceptable salt or solvate thereof~~.

3. (Canceled)

4. (Currently amended): A compound according to claim 1~~, selected from the following group:~~ which is 1-{1-[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4-yl]-1*H*-pyrazol-3-yl}-2-imidazolidinone~~;~~

~~1-{1-[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydro-4-quinazolinyl]-1*H*-pyrazol-3-yl}-2-imidazolidinone; and~~

~~1-{1-[8-(2,4-dichlorophenyl)-2-methyl-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl]-1*H*-pyrazol-3-yl}-2-imidazolidinone; or a prodrug, or a pharmaceutically acceptable salt or solvate thereof~~.

Claims 5-9 (Canceled).

10. (Currently amended): A pharmaceutical composition comprising a compound of claim 1~~, or a prodrug, or a pharmaceutically acceptable salt or solvate thereof,~~ in admixture with one or more physiologically acceptable carriers or excipients.

11. (Canceled)

12. (Currently amended): A method ~~in~~ for the treatment of depression ~~and~~ or anxiety, comprising administration of an effective amount of a compound according to claim 1~~, or a prodrug, or a pharmaceutically acceptable salt or solvate thereof,~~ to a mammal in need thereof.

13. (Currently amended): A method, ~~in~~ for the treatment of IBS (irritable bowel disease) ~~and IBD (inflammatory bowel disease),~~ comprising administration of an effective amount of a compound according to claim 1~~, or a prodrug, or a pharmaceutically acceptable salt or solvate thereof,~~ to a mammal in need thereof.

14. (New) A compound according to formula (Ia)



(Ia)

in which R, R_1, Z, Y, W, A, D, G are defined as in claim 1.

15. (New) A compound according to formula (Ib)



(Ib)

in which R, R_1, Z, Y, W, A, D, G are defined as in claim 1.

16. (New) A compound according to formula (Ic)



(Ic)

in which R, R_1, Z, Y, W, A, D, G are defined as in claim 1.

17. (New) A process for preparing a compound according to claim 14 comprising the following steps:



in which

step a stands for the nucleophilic substitution with an amine of compounds of formula (II), in basic conditions to give compounds (III);

step b stands for the protection of the amino group with a protecting group;

step c stands for the oxidation of the double bond with an oxidizing agent to give the aldehyde of compounds (V);

step d + e stands for formation of the aldehyde group of compounds (VII) through formation of the enol ether by Wittig reaction followed by acid hydrolysis (step e);

step f stands for the reduction of the aldehyde group of compounds (VII) to the alcohol of compounds (VIII) with a reducing agent;

step g stands for the conversion of the alcohol of compounds (VIII) into a leaving group;

step h stands for the deprotection of the amino group of compounds (IX);

step i stands for the intramolecular cyclization to give the cyclized compounds (X); and

step j stands for conversion of the halogen derivative into compounds (Ia), by reaction with a reactive -Z-W derivative, in basic conditions.